149 related articles for article (PubMed ID: 34786859)
1. Engineering pH-Sensitive Stable Nanovesicles for Delivery of MicroRNA Therapeutics.
Boloix A; Feiner-Gracia N; Köber M; Repetto J; Pascarella R; Soriano A; Masanas M; Segovia N; Vargas-Nadal G; Merlo-Mas J; Danino D; Abutbul-Ionita I; Foradada L; Roma J; Córdoba A; Sala S; de Toledo JS; Gallego S; Veciana J; Albertazzi L; Segura MF; Ventosa N
Small; 2022 Jan; 18(3):e2101959. PubMed ID: 34786859
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanocarriers for microRNA delivery.
Scheideler M; Vidakovic I; Prassl R
Chem Phys Lipids; 2020 Jan; 226():104837. PubMed ID: 31689410
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical characterization of pH-responsive and fusogenic self-assembled non-phospholipid vesicles for a potential multiple targeting therapy.
Di Francesco M; Celia C; Primavera R; D'Avanzo N; Locatelli M; Fresta M; Cilurzo F; Ventura CA; Paolino D; Di Marzio L
Int J Pharm; 2017 Aug; 528(1-2):18-32. PubMed ID: 28559215
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA delivery through nanoparticles.
Lee SWL; Paoletti C; Campisi M; Osaki T; Adriani G; Kamm RD; Mattu C; Chiono V
J Control Release; 2019 Nov; 313():80-95. PubMed ID: 31622695
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics.
Cuciniello R; Filosa S; Crispi S
J Exp Clin Cancer Res; 2021 Dec; 40(1):383. PubMed ID: 34863235
[TBL] [Abstract][Full Text] [Related]
6. Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage Cholesterol Efflux in Vitro and in Vivo.
Nguyen MA; Wyatt H; Susser L; Geoffrion M; Rasheed A; Duchez AC; Cottee ML; Afolayan E; Farah E; Kahiel Z; Côté M; Gadde S; Rayner KJ
ACS Nano; 2019 Jun; 13(6):6491-6505. PubMed ID: 31125197
[TBL] [Abstract][Full Text] [Related]
7. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
8. Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models.
Moro M; Di Paolo D; Milione M; Centonze G; Bornaghi V; Borzi C; Gandellini P; Perri P; Pastorino U; Ponzoni M; Sozzi G; Fortunato O
J Control Release; 2019 Aug; 308():44-56. PubMed ID: 31299263
[TBL] [Abstract][Full Text] [Related]
9. Delivery of therapeutic miRNA using polymer-based formulation.
Ban E; Kwon TH; Kim A
Drug Deliv Transl Res; 2019 Dec; 9(6):1043-1056. PubMed ID: 31049843
[TBL] [Abstract][Full Text] [Related]
10. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
11. Physicochemical Biomolecular Insights into Buffalo Milk-Derived Nanovesicles.
Baddela VS; Nayan V; Rani P; Onteru SK; Singh D
Appl Biochem Biotechnol; 2016 Feb; 178(3):544-57. PubMed ID: 26490380
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA replacement therapy in cancer.
Mollaei H; Safaralizadeh R; Rostami Z
J Cell Physiol; 2019 Aug; 234(8):12369-12384. PubMed ID: 30605237
[TBL] [Abstract][Full Text] [Related]
13. Versatile RNA interference nanoplatform for systemic delivery of RNAs.
Choi KY; Silvestre OF; Huang X; Min KH; Howard GP; Hida N; Jin AJ; Carvajal N; Lee SW; Hong JI; Chen X
ACS Nano; 2014 May; 8(5):4559-70. PubMed ID: 24779637
[TBL] [Abstract][Full Text] [Related]
14. Progress in microRNA delivery.
Zhang Y; Wang Z; Gemeinhart RA
J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
[TBL] [Abstract][Full Text] [Related]
15. Chitosan-modified lipid nanovesicles for efficient systemic delivery of l-asparaginase.
Wan S; He D; Yuan Y; Yan Z; Zhang X; Zhang J
Colloids Surf B Biointerfaces; 2016 Jul; 143():278-284. PubMed ID: 27022867
[TBL] [Abstract][Full Text] [Related]
16. Large-scale generation of cell-derived nanovesicles.
Jo W; Kim J; Yoon J; Jeong D; Cho S; Jeong H; Yoon YJ; Kim SC; Gho YS; Park J
Nanoscale; 2014 Oct; 6(20):12056-64. PubMed ID: 25189198
[TBL] [Abstract][Full Text] [Related]
17. Non-viral nanocarriers for intracellular delivery of microRNA therapeutics.
Bai Z; Wei J; Yu C; Han X; Qin X; Zhang C; Liao W; Li L; Huang W
J Mater Chem B; 2019 Feb; 7(8):1209-1225. PubMed ID: 32255160
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticle-mediated delivery of therapeutic genes: focus on miRNA therapeutics.
Muthiah M; Park IK; Cho CS
Expert Opin Drug Deliv; 2013 Sep; 10(9):1259-73. PubMed ID: 23826971
[TBL] [Abstract][Full Text] [Related]
19. MKC-Quatsomes: a stable nanovesicle platform for bio-imaging and drug-delivery applications.
Vargas-Nadal G; Muñoz-Úbeda M; Álamo P; Mitjans M; Céspedes V; Köber M; González-Mira E; Ferrer-Tasies L; Vinardell MP; Mangues R; Veciana J; Ventosa N
Nanomedicine; 2020 Feb; 24():102136. PubMed ID: 31843659
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-targeted therapeutics for lung cancer treatment.
Xue J; Yang J; Luo M; Cho WC; Liu X
Expert Opin Drug Discov; 2017 Feb; 12(2):141-157. PubMed ID: 27866431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
